Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL Trial

• Published in: Clinical infectious diseases Vol. 78; no. 3; pp. 702 - 710
• Main Authors: Jacobs, Tom G, Mumbiro, Vivian, Cassia, Uneisse, Zimba, Kevin, Nalwanga, Damalie, Ballesteros, Alvaro, Domínguez-Rodríguez, Sara, Tagarro, Alfredo, Madrid, Lola, Mutata, Constantine, Chitsamatanga, Moses, Bwakura-Dangarembizi, Mutsa, Passanduca, Alfeu, Buck, W Chris, Nduna, Bwendo, Chabala, Chishala, Najjingo, Elizabeth, Musiime, Victor, Moraleda, Cinta, Colbers, Angela, Mujuru, Hilda A, Rojo, Pablo, Burger, David M
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 20.03.2024
• Subjects: rifampicin; infants; dolutegravir; drug–drug interaction; HIV

Abstract Background We evaluated dolutegravir pharmacokinetics in infants with human immunodeficiency virus (HIV) receiving dolutegravir twice daily (BID) with rifampicin-based tuberculosis (TB) treatment compared with once daily (OD) without rifampicin. Methods Infants with HIV aged 1–12 months, we...